David L Kolin, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endometrial Neoplasms | 12 | 2024 | 1361 | 2.680 |
Why?
|
Carcinoma, Endometrioid | 6 | 2024 | 276 | 1.800 |
Why?
|
Uterine Neoplasms | 5 | 2022 | 1434 | 1.590 |
Why?
|
RNA-Binding Protein EWS | 2 | 2024 | 210 | 1.510 |
Why?
|
Fallopian Tube Neoplasms | 4 | 2024 | 329 | 1.460 |
Why?
|
Vulvar Neoplasms | 3 | 2022 | 265 | 1.430 |
Why?
|
Genital Neoplasms, Female | 2 | 2024 | 538 | 1.150 |
Why?
|
Carcinoma | 6 | 2024 | 2334 | 1.110 |
Why?
|
Endometrial Stromal Tumors | 2 | 2023 | 46 | 1.050 |
Why?
|
Sarcoma, Endometrial Stromal | 2 | 2023 | 93 | 1.020 |
Why?
|
Endodermal Sinus Tumor | 2 | 2022 | 53 | 0.970 |
Why?
|
DNA Helicases | 4 | 2023 | 854 | 0.960 |
Why?
|
Fallopian Tubes | 4 | 2023 | 178 | 0.950 |
Why?
|
Oncogene Fusion | 2 | 2021 | 81 | 0.920 |
Why?
|
Kallikreins | 2 | 2015 | 231 | 0.880 |
Why?
|
Immunohistochemistry | 9 | 2024 | 11064 | 0.850 |
Why?
|
Uterine Cervical Neoplasms | 3 | 2024 | 2018 | 0.810 |
Why?
|
Sarcoma | 3 | 2022 | 1786 | 0.780 |
Why?
|
WT1 Proteins | 1 | 2021 | 184 | 0.720 |
Why?
|
Ovarian Neoplasms | 9 | 2024 | 4875 | 0.710 |
Why?
|
Pelvic Neoplasms | 1 | 2022 | 248 | 0.700 |
Why?
|
Rhabdoid Tumor | 2 | 2022 | 210 | 0.690 |
Why?
|
Vaginal Neoplasms | 1 | 2020 | 105 | 0.690 |
Why?
|
Adenomatoid Tumor | 1 | 2019 | 12 | 0.670 |
Why?
|
Adenocarcinoma | 4 | 2024 | 6310 | 0.660 |
Why?
|
Sarcoma, Synovial | 1 | 2020 | 151 | 0.660 |
Why?
|
Nuclear Proteins | 6 | 2024 | 5793 | 0.650 |
Why?
|
Gene Rearrangement | 2 | 2024 | 1122 | 0.640 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2020 | 194 | 0.610 |
Why?
|
Sex Cord-Gonadal Stromal Tumors | 1 | 2020 | 113 | 0.610 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 1 | 2018 | 77 | 0.560 |
Why?
|
Diagnosis, Differential | 6 | 2024 | 12968 | 0.540 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2018 | 218 | 0.530 |
Why?
|
Neurocutaneous Syndromes | 1 | 2016 | 53 | 0.530 |
Why?
|
Gene Amplification | 1 | 2020 | 1085 | 0.520 |
Why?
|
Melanosis | 1 | 2016 | 93 | 0.500 |
Why?
|
Transcription Factors | 8 | 2024 | 12100 | 0.500 |
Why?
|
Tissue Kallikreins | 1 | 2014 | 14 | 0.490 |
Why?
|
Stomach Neoplasms | 2 | 2015 | 1423 | 0.480 |
Why?
|
Soft Tissue Neoplasms | 2 | 2022 | 1151 | 0.460 |
Why?
|
Cerebrospinal Fluid | 1 | 2016 | 544 | 0.440 |
Why?
|
GTP Phosphohydrolases | 1 | 2016 | 516 | 0.430 |
Why?
|
Neuroendocrine Tumors | 1 | 2018 | 649 | 0.380 |
Why?
|
Receptor, erbB-2 | 2 | 2022 | 2544 | 0.370 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 1729 | 0.370 |
Why?
|
Epigenesis, Genetic | 1 | 2024 | 3758 | 0.360 |
Why?
|
DNA Methylation | 2 | 2024 | 4374 | 0.360 |
Why?
|
Carcinoma, Small Cell | 2 | 2023 | 416 | 0.360 |
Why?
|
Serine Endopeptidases | 1 | 2015 | 1021 | 0.350 |
Why?
|
Tuberous Sclerosis | 1 | 2018 | 1030 | 0.340 |
Why?
|
Endometriosis | 1 | 2018 | 871 | 0.330 |
Why?
|
Spectrum Analysis | 3 | 2008 | 453 | 0.330 |
Why?
|
Rectal Neoplasms | 1 | 2018 | 1151 | 0.320 |
Why?
|
Green Fluorescent Proteins | 5 | 2007 | 2056 | 0.310 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3618 | 0.300 |
Why?
|
Female | 37 | 2024 | 391011 | 0.300 |
Why?
|
Biophysics | 2 | 2006 | 380 | 0.290 |
Why?
|
Cystadenocarcinoma, Serous | 2 | 2024 | 475 | 0.290 |
Why?
|
beta Catenin | 3 | 2024 | 1043 | 0.290 |
Why?
|
Meningeal Neoplasms | 1 | 2016 | 1248 | 0.290 |
Why?
|
Fluorescent Dyes | 4 | 2008 | 1914 | 0.290 |
Why?
|
Integrin alpha5 | 1 | 2006 | 20 | 0.280 |
Why?
|
Actinin | 1 | 2007 | 163 | 0.270 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2024 | 2500 | 0.270 |
Why?
|
Carcinoma in Situ | 2 | 2024 | 796 | 0.260 |
Why?
|
Spectrophotometry | 1 | 2005 | 311 | 0.250 |
Why?
|
Isoxazoles | 2 | 2024 | 230 | 0.250 |
Why?
|
Mesonephroma | 1 | 2024 | 21 | 0.240 |
Why?
|
Peutz-Jeghers Syndrome | 1 | 2024 | 59 | 0.230 |
Why?
|
Adult | 19 | 2024 | 219847 | 0.230 |
Why?
|
Epithelioid Cells | 1 | 2024 | 60 | 0.230 |
Why?
|
Precancerous Conditions | 2 | 2021 | 978 | 0.220 |
Why?
|
Quantum Dots | 3 | 2011 | 168 | 0.220 |
Why?
|
Adnexal Diseases | 1 | 2024 | 104 | 0.220 |
Why?
|
Endometrial Hyperplasia | 1 | 2024 | 98 | 0.220 |
Why?
|
Mullerian Ducts | 1 | 2024 | 201 | 0.220 |
Why?
|
Young Adult | 9 | 2024 | 58673 | 0.210 |
Why?
|
Humans | 40 | 2024 | 760261 | 0.210 |
Why?
|
CHO Cells | 6 | 2008 | 1389 | 0.210 |
Why?
|
Cricetinae | 7 | 2008 | 2427 | 0.210 |
Why?
|
RNA, Satellite | 1 | 2022 | 17 | 0.210 |
Why?
|
Myoepithelioma | 1 | 2022 | 26 | 0.200 |
Why?
|
Middle Aged | 16 | 2024 | 220175 | 0.200 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2022 | 9274 | 0.200 |
Why?
|
Metaplasia | 2 | 2020 | 320 | 0.200 |
Why?
|
Wolffian Ducts | 1 | 2021 | 27 | 0.190 |
Why?
|
Receptor, trkA | 1 | 2022 | 159 | 0.190 |
Why?
|
Vulvar Diseases | 1 | 2021 | 62 | 0.190 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2023 | 243 | 0.190 |
Why?
|
Mutation | 4 | 2023 | 29950 | 0.190 |
Why?
|
Pyrazines | 2 | 2024 | 1200 | 0.180 |
Why?
|
Deoxycytidine | 2 | 2024 | 872 | 0.180 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2022 | 430 | 0.180 |
Why?
|
Microscopy, Fluorescence | 5 | 2008 | 2651 | 0.180 |
Why?
|
Nuclear Receptor Coactivator 3 | 1 | 2020 | 46 | 0.180 |
Why?
|
Nuclear Receptor Coactivator 1 | 1 | 2020 | 42 | 0.180 |
Why?
|
Nuclear Receptor Coactivator 2 | 1 | 2020 | 40 | 0.180 |
Why?
|
Uterine Cervical Diseases | 1 | 2020 | 74 | 0.170 |
Why?
|
Histone Acetyltransferases | 1 | 2022 | 337 | 0.170 |
Why?
|
Cricetulus | 5 | 2008 | 815 | 0.170 |
Why?
|
Membrane Proteins | 1 | 2016 | 7854 | 0.170 |
Why?
|
Vaginal Diseases | 1 | 2020 | 103 | 0.170 |
Why?
|
Hypercalcemia | 1 | 2022 | 421 | 0.160 |
Why?
|
Diffusion | 5 | 2008 | 814 | 0.160 |
Why?
|
Sensitivity and Specificity | 5 | 2024 | 14656 | 0.160 |
Why?
|
Choristoma | 1 | 2020 | 207 | 0.160 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2023 | 896 | 0.160 |
Why?
|
Epithelial Cells | 2 | 2020 | 3665 | 0.150 |
Why?
|
Computer Simulation | 5 | 2008 | 6210 | 0.150 |
Why?
|
BRCA2 Protein | 2 | 2024 | 797 | 0.150 |
Why?
|
Melanoma | 1 | 2016 | 5695 | 0.150 |
Why?
|
Prognosis | 4 | 2023 | 29636 | 0.140 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2022 | 421 | 0.140 |
Why?
|
Leiomyoma | 1 | 2022 | 654 | 0.140 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 493 | 0.140 |
Why?
|
Chromosome Deletion | 1 | 2022 | 1387 | 0.140 |
Why?
|
Aged, 80 and over | 7 | 2024 | 58947 | 0.140 |
Why?
|
Photobleaching | 2 | 2006 | 30 | 0.130 |
Why?
|
Gene Dosage | 1 | 2020 | 1218 | 0.130 |
Why?
|
Predictive Value of Tests | 2 | 2024 | 15273 | 0.130 |
Why?
|
Retrospective Studies | 5 | 2024 | 80301 | 0.130 |
Why?
|
Lymphangioleiomyomatosis | 1 | 2018 | 203 | 0.130 |
Why?
|
DNA Copy Number Variations | 2 | 2023 | 2008 | 0.130 |
Why?
|
Sequence Analysis, RNA | 1 | 2023 | 2003 | 0.130 |
Why?
|
Estrogen Receptor alpha | 1 | 2020 | 580 | 0.130 |
Why?
|
RNA | 2 | 2022 | 2721 | 0.130 |
Why?
|
Homeodomain Proteins | 1 | 2024 | 2414 | 0.120 |
Why?
|
Aged | 10 | 2024 | 168995 | 0.120 |
Why?
|
DNA Replication | 1 | 2021 | 1412 | 0.120 |
Why?
|
Transfection | 3 | 2007 | 5782 | 0.120 |
Why?
|
Uterus | 1 | 2018 | 651 | 0.120 |
Why?
|
Gene Deletion | 1 | 2022 | 2668 | 0.120 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1591 | 0.110 |
Why?
|
Observer Variation | 2 | 2021 | 2596 | 0.110 |
Why?
|
Tissue Array Analysis | 1 | 2015 | 551 | 0.110 |
Why?
|
Mesothelioma | 1 | 2019 | 806 | 0.110 |
Why?
|
Cytodiagnosis | 1 | 2016 | 432 | 0.100 |
Why?
|
Adenoma | 1 | 2023 | 2148 | 0.100 |
Why?
|
Prostate | 1 | 2020 | 1793 | 0.100 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2007 | 8945 | 0.100 |
Why?
|
Adolescent | 5 | 2024 | 87747 | 0.100 |
Why?
|
Recombinant Fusion Proteins | 4 | 2007 | 3735 | 0.090 |
Why?
|
Germ-Line Mutation | 1 | 2018 | 1843 | 0.090 |
Why?
|
Fluorescence | 2 | 2011 | 750 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 2 | 2024 | 5640 | 0.080 |
Why?
|
Reproducibility of Results | 4 | 2020 | 20048 | 0.080 |
Why?
|
Paxillin | 1 | 2007 | 86 | 0.070 |
Why?
|
Lung Neoplasms | 3 | 2022 | 13249 | 0.070 |
Why?
|
Genomics | 1 | 2023 | 5790 | 0.070 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 3613 | 0.070 |
Why?
|
Carbon-Nitrogen Ligases | 1 | 2006 | 27 | 0.070 |
Why?
|
Cell Membrane | 2 | 2006 | 3683 | 0.070 |
Why?
|
Normal Distribution | 1 | 2005 | 273 | 0.060 |
Why?
|
Disease Progression | 1 | 2022 | 13505 | 0.060 |
Why?
|
PAX2 Transcription Factor | 1 | 2024 | 86 | 0.060 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2022 | 11708 | 0.060 |
Why?
|
Survival Rate | 1 | 2018 | 12806 | 0.060 |
Why?
|
Colorectal Neoplasms | 1 | 2023 | 6855 | 0.060 |
Why?
|
Kaplan-Meier Estimate | 1 | 2014 | 6545 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2023 | 5797 | 0.060 |
Why?
|
Microspheres | 1 | 2006 | 785 | 0.050 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2024 | 2927 | 0.050 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2006 | 446 | 0.050 |
Why?
|
Protein Interaction Mapping | 1 | 2006 | 617 | 0.050 |
Why?
|
Microscopy, Confocal | 2 | 2008 | 1972 | 0.050 |
Why?
|
Spectrometry, Fluorescence | 1 | 2005 | 686 | 0.050 |
Why?
|
Cell Differentiation | 1 | 2020 | 11480 | 0.050 |
Why?
|
Proteins | 2 | 2008 | 6030 | 0.050 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2011 | 2536 | 0.050 |
Why?
|
Glypicans | 1 | 2022 | 33 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2023 | 8984 | 0.050 |
Why?
|
Integrins | 1 | 2006 | 840 | 0.050 |
Why?
|
Time Factors | 5 | 2021 | 40133 | 0.050 |
Why?
|
alpha-Fetoproteins | 1 | 2022 | 222 | 0.050 |
Why?
|
Photons | 1 | 2005 | 581 | 0.050 |
Why?
|
Ki-67 Antigen | 1 | 2024 | 631 | 0.050 |
Why?
|
Embryo, Mammalian | 1 | 2007 | 1667 | 0.050 |
Why?
|
Northern Ireland | 1 | 2021 | 37 | 0.050 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2021 | 102 | 0.050 |
Why?
|
Proportional Hazards Models | 1 | 2015 | 12532 | 0.050 |
Why?
|
Risk Assessment | 1 | 2022 | 24086 | 0.050 |
Why?
|
Protein Transport | 1 | 2006 | 1966 | 0.040 |
Why?
|
Fibroblasts | 2 | 2007 | 4091 | 0.040 |
Why?
|
Nanoparticles | 1 | 2011 | 1938 | 0.040 |
Why?
|
Light | 1 | 2005 | 1344 | 0.040 |
Why?
|
Neprilysin | 1 | 2022 | 472 | 0.040 |
Why?
|
Actins | 1 | 2006 | 2049 | 0.040 |
Why?
|
Escherichia coli Proteins | 1 | 2006 | 1066 | 0.040 |
Why?
|
Animals | 10 | 2023 | 167940 | 0.040 |
Why?
|
Treatment Outcome | 2 | 2022 | 64947 | 0.040 |
Why?
|
Child | 2 | 2024 | 79758 | 0.040 |
Why?
|
PTEN Phosphohydrolase | 1 | 2024 | 1115 | 0.040 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2022 | 730 | 0.040 |
Why?
|
North America | 1 | 2021 | 1282 | 0.040 |
Why?
|
BRCA1 Protein | 1 | 2024 | 1146 | 0.040 |
Why?
|
Transsexualism | 1 | 2020 | 177 | 0.040 |
Why?
|
Artifacts | 1 | 2005 | 1893 | 0.030 |
Why?
|
Algorithms | 3 | 2006 | 13967 | 0.030 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2006 | 3335 | 0.030 |
Why?
|
Oncogenes | 1 | 2021 | 1221 | 0.030 |
Why?
|
Ligands | 1 | 2022 | 3277 | 0.030 |
Why?
|
Repressor Proteins | 1 | 2006 | 2978 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2022 | 21065 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2007 | 18968 | 0.030 |
Why?
|
Hormone Replacement Therapy | 1 | 2020 | 756 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2022 | 2202 | 0.030 |
Why?
|
Male | 3 | 2016 | 359413 | 0.030 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2022 | 2866 | 0.030 |
Why?
|
Androgens | 1 | 2020 | 1289 | 0.030 |
Why?
|
Mice | 4 | 2023 | 81216 | 0.030 |
Why?
|
Models, Biological | 2 | 2006 | 9468 | 0.030 |
Why?
|
Models, Statistical | 1 | 2005 | 5073 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7236 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3810 | 0.020 |
Why?
|
Testosterone | 1 | 2020 | 2469 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 3826 | 0.020 |
Why?
|
Chromogenic Compounds | 1 | 2007 | 31 | 0.020 |
Why?
|
Streptavidin | 1 | 2007 | 82 | 0.020 |
Why?
|
Glycosylphosphatidylinositols | 1 | 2007 | 90 | 0.020 |
Why?
|
Stochastic Processes | 1 | 2008 | 354 | 0.020 |
Why?
|
Fluorescence Recovery After Photobleaching | 1 | 2006 | 53 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2022 | 8498 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11141 | 0.020 |
Why?
|
5'-Nucleotidase | 1 | 2007 | 161 | 0.020 |
Why?
|
Models, Chemical | 1 | 2008 | 614 | 0.020 |
Why?
|
Cell Line, Tumor | 1 | 2022 | 16905 | 0.020 |
Why?
|
Histidine | 1 | 2006 | 311 | 0.020 |
Why?
|
Databases, Factual | 1 | 2021 | 8018 | 0.020 |
Why?
|
Biotin | 1 | 2006 | 253 | 0.020 |
Why?
|
3T3 Cells | 1 | 2006 | 1085 | 0.020 |
Why?
|
Registries | 1 | 2021 | 8449 | 0.010 |
Why?
|
Phenotype | 1 | 2022 | 16543 | 0.010 |
Why?
|
Luminescent Proteins | 1 | 2006 | 835 | 0.010 |
Why?
|
Cell Line | 2 | 2007 | 15626 | 0.010 |
Why?
|
Cytoplasm | 1 | 2006 | 1518 | 0.010 |
Why?
|
Cytoskeleton | 1 | 2006 | 1167 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2005 | 2262 | 0.010 |
Why?
|
Cytoskeletal Proteins | 1 | 2006 | 1344 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2011 | 5498 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2006 | 3096 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2011 | 9531 | 0.010 |
Why?
|
Protein Binding | 1 | 2008 | 9336 | 0.010 |
Why?
|
Risk Factors | 1 | 2020 | 74269 | 0.010 |
Why?
|
Kidney | 1 | 2006 | 7072 | 0.010 |
Why?
|